dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gallardo Lopez, Victor José |
dc.contributor.author | Torres Ferrús, Marta |
dc.contributor.author | Sánchez-Mateo, N.M. |
dc.contributor.author | Viguera-Romero, J. |
dc.contributor.author | Pozo Rosich, Patricia |
dc.contributor.author | Alpuente Ruiz, Alicia |
dc.contributor.author | Caronna, Edoardo |
dc.date.accessioned | 2021-11-25T13:42:50Z |
dc.date.available | 2021-11-25T13:42:50Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Sánchez-Mateo NM, Viguera-Romero J, et al. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications. Neurologia. 2021 Oct;36:611–7. |
dc.identifier.issn | 0213-4853 |
dc.identifier.uri | https://hdl.handle.net/11351/6601 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Anticossos monoclonals; Migranya |
dc.description.sponsorship | No funding was received for this study. |
dc.language.iso | eng |
dc.publisher | Elsevier España |
dc.relation.ispartofseries | Neurología;36 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Migranya - Tractament |
dc.subject | Migranya - Efecte dels medicaments |
dc.subject | COVID-19 (Malaltia) |
dc.subject.mesh | Migraine Disorders |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Coronavirus Infections |
dc.title | Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications |
dc.title.alternative | Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.nrl.2021.03.003 |
dc.subject.decs | trastornos migrañosos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | https://doi.org/10.1016/j.nrleng.2021.03.005 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gallardo, VJ] Grup de recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sánchez-Mateo NM] Headache Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Viguera-Romero J] Headache Unit, Neuroscience Department, Hospital Universitario Virgen Macarena, Sevilla, Spain |
dc.identifier.pmid | 33832802 |
dc.identifier.wos | 000703606400006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |